Dual pneumococcal and influenza vaccination: severe concerns about the composition of the control groups.
Miquel B
MB
Ekkelenkamp
Marc J M
MJ
Bonten
D000368:Aged; D002318:Cardiovascular Diseases / Q000401:mortality / Q000517:prevention & control; D002561:Cerebrovascular Disorders / Q000401:mortality / Q000517:prevention & control; D035061:Control Groups; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007251:Influenza, Human / Q000150:complications / Q000401:mortality / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D011018:Pneumonia, Pneumococcal / Q000150:complications / Q000401:mortality / Q000517:prevention & control*; D014611:Vaccination / Q000379:methods*
C414006:23-valent pneumococcal capsular polysaccharide vaccine; D007252:Influenza Vaccines; D022242:Pneumococcal Vaccines